Treatment beyond progression and locoregional approaches in selected patients with BRAF-mutated metastatic melanoma

Treatment beyond progression and locoregional approaches in selected patients with BRAF-mutated metastatic melanoma

The clinical management of BRAF-mutated metastatic melanoma had an important turning point after the introduction of the targeted therapy. Despite the efficacy and good tolerability of this treatment, the development of resistance mechanisms causes disease progression. The aim of this review is to i...

Full description

Bibliographic Details
Main Authors:	Francesco Serra, Carlotta Faverio, Angioletta Lasagna, Stefania Barruscotti, Tommaso Dominioni, Marco Benazzo, Paolo Pedrazzoli, Silvia Chiellino
Format:	Article
Language:	English
Published:	BioExcel Publishing Ltd 2021-08-01
Series:	Drugs in Context
Subjects:	braf-mutated metastatic melanoma locoregional approaches targeted therapy treatment beyond progression
Online Access:	https://www.drugsincontext.com/treatment-beyond-progression-and-locoregional-approaches-in-selected-patients-with-braf-mutated-metastatic-melanoma

Similar Items

Clinical significance of <it>BRAF </it>mutations in metastatic melanoma
by: Polsky David, et al.
Published: (2004-12-01)

The Prognostic Value of Locoregional Interventions for BRAF V600E Metastatic Colorectal Cancer: A Retrospective Cohort Analysis
by: Liu-Fang Ye, et al.
Published: (2021-08-01)

Current Advances in the Treatment of BRAF-Mutant Melanoma
by: Hima Patel, et al.
Published: (2020-02-01)

BRAF V600E MUTATIONS IN METASTATIC MELANOMA - CASE REPORT
by: Ivana Inić, et al.
Published: (2014-09-01)

Factors influencing the prognosis in Braf wild-type metastatic malignant melanoma and the role of novel inflammation indices
by: Senar Ebinç, et al.
Published: (2023-09-01)

Clinical Implications of Acquired BRAF Inhibitors Resistance in Melanoma
by: Paola Savoia, et al.
Published: (2020-12-01)

The Impact of Drug–Drug Interactions on the Toxicity Profile of Combined Treatment with BRAF and MEK Inhibitors in Patients with BRAF-Mutated Metastatic Melanoma
by: Silvia Mezi, et al.
Published: (2023-09-01)

A Dramatic Response to Second-Line Nivolumab and Ipilimumab in BRAF-V600-Mutated Metastatic Melanoma
by: Dahlia Fedele, et al.
Published: (2024-01-01)

NAMPT Over-Expression Recapitulates the BRAF Inhibitor Resistant Phenotype Plasticity in Melanoma
by: Valentina Audrito, et al.
Published: (2020-12-01)

Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive <i>BRAF</i> Mutant Advanced Melanoma
by: Ernesto Rossi, et al.
Published: (2023-01-01)

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
by: Ernesto Rossi, et al.
Published: (2019-04-01)

A Rare Complex BRAF Mutation Involving Codon V600 and K601 in Primary Cutaneous Melanoma: Case Report
by: Francesca Consoli, et al.
Published: (2020-07-01)

BRAF L485–P490 deletion mutant metastatic melanoma sensitive to BRAF and MEK inhibition: A case report and literature review
by: Simeng Zhang, et al.
Published: (2023-01-01)

The Transcriptional Landscape of <i>BRAF</i> Wild Type Metastatic Melanoma: A Pilot Study
by: Elena Lastraioli, et al.
Published: (2022-06-01)

Current State of Target Treatment in BRAF Mutated Melanoma
by: Enrica Teresa Tanda, et al.
Published: (2020-07-01)

Case Report: Rechallenge With BRAF and MEK Inhibitors in Metastatic Melanoma: A Further Therapeutic Option in Salvage Setting?
by: Anna Stagno, et al.
Published: (2021-05-01)

Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside
by: Taku Fujimura, et al.
Published: (2019-09-01)

Modern options in personalized therapy of metastatic cutaneous melanoma
by: S A Protsenko, et al.
Published: (2014-09-01)

Baseline Genomic Features in <i>BRAFV600</i>-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care
by: Baptiste Louveau, et al.
Published: (2019-08-01)

Metastatic melanoma and vemurafenib: novel approaches
by: Ramon Andrade De Mello
Published: (2012-04-01)

The Pattern of Progression to First-Line Treatment with Dabrafenib and Trametinib in Patients with Unresectable or Metastatic, BRAF-Mutated, Cutaneous Melanoma: Results of the Observational T-WIN Study
by: Michele Del Vecchio, et al.
Published: (2023-03-01)

Braf protein mutation and its significancy within patients with melanoma
by: Julia Kuchnicka, et al.
Published: (2022-08-01)

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing
by: Gulietta M. Pupo, et al.
Published: (2017-05-01)

Predictive Evaluation on Cytological Sample of Metastatic Melanoma: The Role of BRAF Immunocytochemistry in the Molecular Era
by: Andrea Ronchi, et al.
Published: (2021-06-01)

Case Report: Dynamic overlap of melanoma, sarcoidosis, and targeted therapy for BRAF-mutant melanoma
by: Nakul Dar, et al.
Published: (2023-08-01)

Arthralgia Induced by BRAF Inhibitor Therapy in Melanoma Patients
by: Martin Salzmann, et al.
Published: (2020-10-01)

Case report: Exceptional disease progression in a 70-year-old patient: generalized melanosis and melanuria in the course of metastatic melanoma - a case study
by: Jacek Calik, et al.
Published: (2024-01-01)

BRAF V600 Mutation Profile of Metastatic Melanoma in the Thrace Region of Turkey
by: Nuray CAN, et al.
Published: (2018-05-01)

Advances in Intralesional Therapy for Locoregionally Advanced and Metastatic Melanoma: Five Years of Progress
by: Danielle K. DePalo, et al.
Published: (2023-02-01)

Comparison of Two Rapid Assays for the Detection of <i>BRAF</i> V600 Mutations in Metastatic Melanoma including Positive Sentinel Lymph Nodes
by: Elodie Long-Mira, et al.
Published: (2022-03-01)

The Role of Treatment Sequencing with Immune-Checkpoint Inhibitors and BRAF/MEK Inhibitors for Response and Survival of Patients with BRAFV600-Mutant Metastatic Melanoma—A Retrospective, Real-World Cohort Study
by: Maximilian Haist, et al.
Published: (2022-04-01)

Potential utilization of neopterin measurements in the assessment of pyrexia in metastatic melanoma treated with combined targeted therapy: a case report
by: Bartoušková Marie, et al.
Published: (2020-08-01)

Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma
by: Saba S. Shaikh, et al.
Published: (2022-11-01)

Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitors
by: Dolinsek Tanja, et al.
Published: (2016-09-01)

Locoregional therapy in de novo metastatic breast cancer: Systemic review and meta-analysis
by: Daniel Reinhorn, et al.
Published: (2021-08-01)

Triple Combination of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in <i>BRAF</i>V600 Melanoma: Current Status and Future Perspectives
by: Michèle Welti, et al.
Published: (2022-11-01)

Combination of encorafenib and binimetinib in the treatment of patients with <i>BRAF</i>-mutated advanced melanoma. Case report
by: Kristina V. Orlova, et al.
Published: (2023-05-01)

Surgical series of metastatic cerebral melanoma: Clinical association of resection, BRAF-mutation status, and survival
by: M.J. Colditz, et al.
Published: (2021-06-01)

Effects of locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: A real-world study
by: Fujuan Zeng, et al.
Published: (2021-11-01)

Defining the Criteria for Reflex Testing for <i>BRAF</i> Mutations in Cutaneous Melanoma Patients
by: Sarah Zhou, et al.
Published: (2021-05-01)